Prime-boost immunization of codon optimized HIV-1 CRF01AE Gag in BCG with recombinant vaccinia virus Elicits MHC class i and II immune responses in mice

Immunological Investigations

Volumn 38, Issue 8, 2009, Pages 762-779

  Promkhatkaew, Duanthanorm ^a   Pinyosukhee, Nadthanan ^a   Thongdeejaroen, Wilai ^a   Teeka, Jantima ^a   Wutthinantiwong, Preeda ^a   Leangaramgul, Preecha ^a   Sawanpanyalert, Pathom ^a   Warachit, Paijit ^b  

^a Medical Biotechnology Center   (Thailand)

^b MINISTRY OF PUBLIC HEALTH   (Thailand)

Author keywords

BCG; Codon usage; HIV vaccine; Prime boost immunization; Vaccinia virus

Indexed keywords

BCG VACCINE; GAG PROTEIN; GAMMA INTERFERON; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN GAG E; UNCLASSIFIED DRUG; VACCINIA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CODON; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; IMMUNIZATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS EXPRESSION;

AIDS VACCINES; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CODON; CYTOTOXICITY, IMMUNOLOGIC; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC ENGINEERING; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HIV INFECTIONS; HIV-1; IMMUNIZATION, SECONDARY; INTERFERON-GAMMA; INTERLEUKIN-2; MICE; MICE, INBRED BALB C; MYCOBACTERIUM BOVIS; VACCINES, SYNTHETIC; VACCINIA;

EID: 70350749667     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820130903070544     Document Type: Article

References (30)

1. Andre, S., Seed, B., Eberle, J., Schraut, W., Bultmann, A., Haas, J. (1998). Increased immune response elicited by DNA vaccination with synthetic gp120 sequence with optimized codon usage. J. Virol. 72(2):1497-1503.
2. Bertoletti, A., Cham, F., McAdam, Rostron, T., Rowland-Jones, S., Sabaly, S., Corrah, T., Ariyoshi, K., Whittle, H. (1998). Cytotoxic T cells from HIV-2 infected patients frequenctly cross-react with different HIV-1 clades. J. Virol. 22:2439-2448.
3. Betts, M. R., Krowska, J., Santamaria, C., Balsamo, K., Gao, R., Mulunda, G., Luo, C. W., Gandu, N. N., Sheppard, H. H., Hahn, B. H., Allen, S., Frelinger, J. A. (1997). Cross-clade HIV-1 specific cytotoxic T-lymphocyte responses in HIV-infected Zambians. J. Virol. 71:8908-8911.
4. Casimiro, D. R., Chen, L., Fu, T., Evans, R. K., Caulfield, M. J., Davies, M., Tang, A., Chen, M, Huang, L, Harris, V, Freed, D. C., Wilson, K. A., Dubey, S., Zhu, D. M., Nawrocki, D., Mach, H., Troutman, R., Isopi, L., Williams, D., Hurni, W., Xu, Z., Smith, J. G., Wang, S., Liu, X., Gua,n L., Long, R., Trigona, W., Heidecker, G. J., Perry, H. C., Persaud, N., Su, Q, Liang, X., Youi, I. R., Chastain, M., Bett, A. J., Volkin, D. B., Emini, E. A., Shiver, J. W. (2003). Comparative immunogenicity in rhesus monkeys of DNA plasmid recombinant vaccinia virus, and replicationdefective adenovirus vectors expressing a HIV-1 gag gene. J. Virol. 77(11): 6305-6313.
5. Clerici, M., Shearer, G. (1996). Correlates of protection in HIV infection and the progression of HIV infection to AIDS. Immunol. Lett. 51:69-73. (Pubitemid 26227473)
6. Delves, P. J., Roitt, I. M. (2000). The immune system. First of two parts. N. Eng. J. Med. 343:37-49.
7. Deml, L., Bojak, A., Steck, S., Graf, M., Wild, J., Schirmbeck, R., Wolf, H., Wagner, R. (2001). Multiple effects of codon usage optimization on expression and immunogenicitiy of DNA candidate vaccines encoding the HIV-1 gag protein. J. Virol. 75(22): 10991-11001.
8. Durali, D., Mowan, J., Letourneur, F., Schmitt, D., Guegan, N., Dalod, M., Sarogosti, S., Sicard D., Levy J. P., Gomard, E. (1998). Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients. .J. Virol. 72:3547-3553.
9. Engelmayer, J., Larsson, M., Lee, M., Cox, W. I., Steinman, R. M., Bhardwaj, N. (2001). Mature Dendritic cells infected with canary pox virus elicit strong anti-HIV CD8+ and CD4+ T cell responses from chronically infected individuals. J. Virol. 75:2142-2153.
10. Gonzalo, R. M., Rodriguez, D., Garcia-Sastre, A., Rodriguez, J. R., Palese, P., Estaban, M. (1999). Enhanced CD8+ T cell response to HIV env by combined immunization with influenza and vaccinia virus recombinant. Vaccine 17:887-892.
11. Hanke, T., Blanchard, T. J., Schneider, J., Hannan, C. M., Becker, M., Gilbert, S. C., Hill, A. V. S., Smith, G. L., McMichael, A. (1998). Enhancement of MHC class I restricted peptide-specific T cell induction by a DNA prime-MVA boost vaccination regime. Vaccine 16:439-446.
12. Huygen, K. E., Lozes, B., Gilles, A., Drowart, K., Palfliet, F., Jurion, I., Roland, M., Art, M., Dufaux, J., Nyabenda, J., de Bruyn, J., Vooren, J. V., DeLeys, R. (1994). Mapping of TH1 helper T cell epitopes on major secreted Mycobacterial antigen 85A in mice infected with live Mycobacterium bovis BCG. Infect. Immun. 62(2):363-370.
13. Im, E. J., Saubi, N., Virgili, G., Sander, C., Teoh, D., Gatell, J. M., McShane, H., Joseph, J., Hanke, T. (2007). Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding. J. Virol. 81(17):9408-9418.
14. Ishii, K., Ueda, Y., Matsuo, K., Matsuura, Y., Kitamura, T., Kato, K., Izumi, Y., Someya K., Ohsu, T., Honda, M., Miyamura, T. (2002). Structural analysis of vaccinia virus DIs strain: Application as a new replication- deficient viral vector. Virology 302:433-444.
15. Janssen, E. M., Lemmens, E. E., Wolfe, T., Christen, U., Von Herrath, M. G., Schoenberger, S. P. (2003). CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421:852-858.
16. Kitamura, T., Kitamura, Y., Tagaya, I. (1967). Immunogenicity of an attenuated strain of vaccinia virus on rabbits and monkeys. Nature 215:1187-1188.
17. Kostsopoulou, E., Kim, V. N., Kingsman, A. J., Kingsman, S. M., Mitrophanous, K. A. (2000). A rev-independent human immunodeficiency virus type1 (HIV-1) based vector that exploits a codon-optimized HIV-1 gag-pol gene. J. Virol. 74(10): 4839-4852.
18. Li, S., Rodriguez, M., Rodriguez, D., Rodriguez, J. R., Estaban, M., Palese, P., Nussenzweig, R. S., Zavala, F. (1993). Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell medicated protective immunity against malaria. Proc. Natl. Acad. Sci. USA 85(9): 3105-3109.
19. Matsumoto, S., Tamaki, M., Yukitaki, H., Matsuo, T., Naito, M., Teraoka, H., Yamada, T. (1996). A stable Escherichia coli-Mycobacterium shuttle vector 'pSO246' in Mycobacterium bovis BCG. FEMS. Microbiol. Lett. 15135(23):237-243.
20. Matsuo, K., Nishino, Y., Kimura, T., Yamaguchi, R., Yamazaki, A., Mikami, T., Ikuta, K. (1992). Highly conserved epitope domain in major core protein p24 is structurally similar among human, simian, and feline immunodeficiency viruses. J. Gen. Virol. 73:2445-2450.
21. Megede, J. Z., Chen, M., Doe, B., Schaefer, M., Greer, C. E., Selby, M., Otten, G. R., Barnette, S. W. (2000). Increased expression and immunogenicity of sequencemodified HIV-1 gag gene. J. Virol. 74(6):2628-2635.
22. Miyahara, Y., Garcia-Sastre, A., Rodriguez, D., Rodriguez, J. R., Tsujii, M., Palese, P., Esteban, M., Zavala, F., Nussenzweig, R. S. (1998). Recombinant viruses expressing a human malaria antigen elicit a protective immune response in mice. Proc. Natl. Acad. Sci. USA 95:3954-3959.
23. Nathan, C. F., Murray, H. W., Wiebe, M. E., Rubin, B. Y. (1983). Identification of IFN-g as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J. Exp. Med. 153:670-689.
24. Pinto, A. R., Fitzgerald, J. C., Giles-Davis, W., Gao, G. P., Wilson, J. M., Ert, H. C. J. (2003). Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. J. Immunol. 171:6774-6779.
25. Promkhatkaew, D., Matsuo, K., Pinyosukhee, N., Thongdeejaroen, W., Leang-aramgul, P., Sawanpanyalert, P., Warachit, P. (2009a). Prime-boost vaccination using recombinant Mycobacterium bovis BCG and recombinant vaccinia virus DIs harbouring HIV-1 CRF01-AE Gag in mice: Influence of immunization routes. Southeast Asian J. Trop. Med. Publ. Health 40(2):273-281.
26. Promkhatkaew, D., Pinyosukhee, N., Thongdeejaroen, W., Sutthent, R., Sawanpanyalert, P., Warachit, P. (2009b). Enhancement of cell-mediated immune response in mice by whole HIV-1 Gag in Mycobacterium bovis BCG as a live vaccine candidate. Southeast Asian J. Trop. Med. Publ. Health 40(1):113-122.
27. Ramakrishna, L., Anand, K. K., Mohankumar, K. M., Ranga, U. (2004). Codon optimization of the tat antigen of HIV-1 generates strong immune response in mice following genetic immunization. J. Virol. 78(17):9174-9189.
28. Seder, R. A., Hill, A. V. (2000). Vaccines against intracellular injections requiring cellular immunity. Nature 406:793-798.
29. Smith, S. M., Malin, A. S., Lukey, P. T., Atkinson, S. E., Content, J., Huygen, K., Dockrel, H. M. (1999). Characterization of human Mycobacterium bovis Bacille Calmette-Guerin-reactive CD8+T cells. Infect. Immun. 67(10):5223-5230.
30. Tagaya, I., Kitamura, T., Sano, Y. (1961). A new mutant of dermovaccinia virus. Nature 192:381-382.